New hope for debilitating fatigue? trial tests drug combo for ME/CFS and long COVID
NCT ID NCT06366724
Summary
This study is testing whether two existing medications, pyridostigmine and low-dose naltrexone, can help improve symptoms and function for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID. It will involve 160 adults who have these conditions with a specific problem called orthostatic intolerance. Participants will be randomly assigned to receive one of the drugs, both, or a placebo for about three months to see if the treatments help with energy, exercise capacity, and daily symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.